LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
Separately, JMP Securities initiated coverage on shares of LeMaitre Vascular in a research note on Monday, October 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $67.60.
LeMaitre Vascular Stock Performance
Shares of NASDAQ LMAT opened at $58.87 on Tuesday. LeMaitre Vascular has a fifty-two week low of $44.27 and a fifty-two week high of $68.67. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of 48.65, a PEG ratio of 2.86 and a beta of 0.84. The firm’s 50-day simple moving average is $55.05 and its 200 day simple moving average is $55.66.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.33 EPS for the quarter, beating the consensus estimate of $0.31 by $0.02. The firm had revenue of $47.40 million during the quarter, compared to analyst estimates of $47.58 million. LeMaitre Vascular had a net margin of 14.69% and a return on equity of 9.83%. The company’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter last year, the business posted $0.25 EPS. On average, sell-side analysts predict that LeMaitre Vascular will post 1.34 EPS for the current year.
Insider Transactions at LeMaitre Vascular
In other news, CEO George W. Lemaitre sold 22,288 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $54.42, for a total transaction of $1,212,912.96. Following the completion of the sale, the chief executive officer now owns 2,269,475 shares in the company, valued at approximately $123,504,829.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO George W. Lemaitre sold 22,288 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $54.42, for a total transaction of $1,212,912.96. Following the completion of the sale, the chief executive officer now owns 2,269,475 shares in the company, valued at approximately $123,504,829.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 24,869 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $54.71, for a total transaction of $1,360,582.99. Following the sale, the chief executive officer now owns 2,312,857 shares of the company’s stock, valued at approximately $126,536,406.47. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of LMAT. Citigroup Inc. boosted its holdings in LeMaitre Vascular by 6.6% in the 1st quarter. Citigroup Inc. now owns 20,987 shares of the medical instruments supplier’s stock worth $975,000 after buying an additional 1,293 shares during the period. MetLife Investment Management LLC boosted its holdings in LeMaitre Vascular by 58.0% in the 1st quarter. MetLife Investment Management LLC now owns 12,092 shares of the medical instruments supplier’s stock worth $562,000 after buying an additional 4,441 shares during the period. Rhumbline Advisers boosted its holdings in LeMaitre Vascular by 8.2% in the 1st quarter. Rhumbline Advisers now owns 95,806 shares of the medical instruments supplier’s stock worth $4,452,000 after buying an additional 7,266 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in LeMaitre Vascular by 14.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,567 shares of the medical instruments supplier’s stock worth $770,000 after buying an additional 2,042 shares during the period. Finally, BlackRock Inc. boosted its holdings in LeMaitre Vascular by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,175,432 shares of the medical instruments supplier’s stock valued at $147,562,000 after purchasing an additional 28,008 shares during the period. 84.64% of the stock is owned by institutional investors.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.